Russia to allocate $1.72 billion annually for procurements of anti-cancer drugs

6 November 2025

The Russian government has approved the allocation of 140 billion roubles ($1.72 billion) annually for the treatment of cancer patients for years to come.

The funds are included in the budget of the Federal Compulsory Medical Insurance Fund, which is designed for the period of 2026-2028.

As part of state plans, the funds will be distributed among the Russian regions in the form of inter-budget transfers from the federal budget.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Pharmaceutical